Do analysts rate CPHI or BCAB?

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CPHI or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. BioAtla's return on equity of 0.00% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% BioAtla N/A N/A -325.64%

Is BCAB or MDCX more profitable?

BioAtla's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Medicus Pharma N/A -3,137.84% -311.33%

Is BCAB or TVGN more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Tevogen Bio N/A N/A -472.77%

Is SKYE or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% BioAtla N/A N/A -325.64%

BioAtla (BCAB) Competitors

$4.19 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.07 -0.12 (-2.89%)

As of 07/2/2026 07:57 PM Eastern

Compare

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include China Pharma (CPHI), Medicus Pharma (MDCX), Tevogen Bio (TVGN), Skye Bioscience (SKYE), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to China Pharma?

China Pharma (NYSE:CPHI) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

BioAtla has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. BioAtla's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
BioAtla	N/A	N/A	-325.64%

77.2% of BioAtla shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

China Pharma has higher revenue and earnings than BioAtla. China Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.29	-$3.08M	-$0.55	N/A
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A

China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

In the previous week, China Pharma's average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
China Pharma	Neutral
BioAtla	Neutral

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioAtla beats China Pharma on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Medicus Pharma?

BioAtla (NASDAQ:BCAB) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given BioAtla's higher possible upside, research analysts clearly believe BioAtla is more favorable than Medicus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Medicus Pharma and 0 mentions for BioAtla. Medicus Pharma's average media sentiment score of 0.61 beat BioAtla's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAtla	Neutral
Medicus Pharma	Positive

BioAtla's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Medicus Pharma	N/A	-3,137.84%	-311.33%

BioAtla has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

Medicus Pharma has lower revenue, but higher earnings than BioAtla. Medicus Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

77.2% of BioAtla shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioAtla and Medicus Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does BioAtla compare to Tevogen Bio?

BioAtla (NASDAQ:BCAB) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

BioAtla has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Tevogen Bio	N/A	N/A	-472.77%

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 4,673.27%. Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tevogen Bio has lower revenue, but higher earnings than BioAtla. Tevogen Bio is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

77.2% of BioAtla shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tevogen Bio had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for BioAtla. Tevogen Bio's average media sentiment score of 0.67 beat BioAtla's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAtla	Neutral
Tevogen Bio	Positive

Summary

BioAtla beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

BioAtla's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
BioAtla	N/A	N/A	-325.64%

Skye Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 1,113.42%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Skye Bioscience had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for BioAtla. Skye Bioscience's average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
BioAtla	Neutral

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Skye Bioscience has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Skye Bioscience has higher earnings, but lower revenue than BioAtla. Skye Bioscience is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A

Summary

Skye Bioscience beats BioAtla on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Marker Therapeutics?

BioAtla (NASDAQ:BCAB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Marker Therapeutics had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Marker Therapeutics and 0 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
Marker Therapeutics	Neutral

Marker Therapeutics has lower revenue, but higher earnings than BioAtla. Marker Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 580.27%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioAtla has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. BioAtla's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Summary

BioAtla and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.94M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.10	21.61	28.02	24.70
Price / Sales	3.48	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-0.15	8.66	10.96	6.46
Net Income	-$59.61M	$23.81M	$3.57B	$337.01M
7 Day Performance	13.86%	3.39%	2.12%	1.69%
1 Month Performance	25.83%	10.81%	5.25%	3.81%
1 Year Performance	-77.95%	62.61%	33.29%	23.90%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.3706 of 5 stars	$4.19 flat	$200.00 +4,673.3%	-77.9%	$6.94M	$2M	N/A	60	Gap Down
CPHI China Pharma	N/A	$0.62 -1.8%	N/A	-61.0%	$25.12M	$3.99M	N/A	250	Gap Down
MDCX Medicus Pharma	3.4409 of 5 stars	$0.44 -9.6%	$9.00 +1,940.8%	-87.7%	$24.99M	N/A	N/A	N/A	Short Interest Decrease Gap Down
TVGN Tevogen Bio	1.9459 of 5 stars	$5.85 -6.9%	$100.00 +1,608.2%	-90.7%	$24.49M	N/A	N/A	3	Positive News
SKYE Skye Bioscience	2.0049 of 5 stars	$0.70 +3.7%	$8.50 +1,123.0%	-84.7%	$24.42M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

How does BioAtla compare to China Pharma?

Summary

How does BioAtla compare to Medicus Pharma?

Summary

How does BioAtla compare to Tevogen Bio?

Summary

How does BioAtla compare to Skye Bioscience?

Summary

How does BioAtla compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

How does BioAtla compare to China Pharma?

Is CPHI or BCAB more profitable?

Do insiders and institutionals have more ownership in CPHI or BCAB?

Which has stronger valuation and earnings, CPHI or BCAB?

Which has more risk & volatility, CPHI or BCAB?

Does the media prefer CPHI or BCAB?

Do analysts rate CPHI or BCAB?

Summary

How does BioAtla compare to Medicus Pharma?

Do analysts recommend BCAB or MDCX?

Does the media refer more to BCAB or MDCX?

Is BCAB or MDCX more profitable?

Which has more volatility and risk, BCAB or MDCX?

Which has stronger earnings & valuation, BCAB or MDCX?

Do institutionals & insiders hold more shares of BCAB or MDCX?

Summary

How does BioAtla compare to Tevogen Bio?

Which has more volatility and risk, BCAB or TVGN?

Is BCAB or TVGN more profitable?

Do analysts prefer BCAB or TVGN?

Which has higher earnings and valuation, BCAB or TVGN?

Do insiders & institutionals have more ownership in BCAB or TVGN?

Does the media favor BCAB or TVGN?

Summary

How does BioAtla compare to Skye Bioscience?

Is SKYE or BCAB more profitable?

Do analysts rate SKYE or BCAB?

Does the media refer more to SKYE or BCAB?

Do institutionals & insiders believe in SKYE or BCAB?

Which has more volatility & risk, SKYE or BCAB?

Which has preferable earnings and valuation, SKYE or BCAB?

Summary

How does BioAtla compare to Marker Therapeutics?

Does the media favor BCAB or MRKR?

Which has higher earnings & valuation, BCAB or MRKR?

Do analysts prefer BCAB or MRKR?

Do institutionals & insiders hold more shares of BCAB or MRKR?

Is BCAB or MRKR more profitable?

Which has more volatility and risk, BCAB or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools